XML 127 R113.htm IDEA: XBRL DOCUMENT v3.22.4
SHARE-BASED PAYMENT - Schedule of Effective Time Fair Value of the Stock Options was Determined Using the BLM (Details) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Number of Shares    
Number of shares, outstanding at beginning (in shares) 33,503,657  
Number on non-vested shares, grant (in shares) 2,900,000  
Number of shares, forfeited (in shares) (312,586)  
Number of shares, outstanding at ending (in shares) 36,091,071 33,503,657
Number of shares, expected to vest and exercisable (in shares) 36,091,071  
Number of shares, exercisable (in shares) 11,875,830  
Weighted Average Exercise Price (US$)    
Weighted average exercise price, outstanding at beginning (in dollars per share) $ 6.19  
Weighted average grant date fair value per share, non-vested shares, grant (in dollars per share) 4.81  
Weighted average exercise price, forfeited (in dollars per share) 6.28  
Weighted average exercise price, outstanding at ending (in dollars per share) 6.08 $ 6.19
Weighted average exercise price, expected to vest and exercisable (in dollars per share) 6.08  
Weighted average exercise price, exercisable (in dollars per share) 6.20  
Weighted Average Grant Date Fair Value (US$)    
Weighted average grant date fair value, outstanding at beginning (in dollars per share) 4.95  
Weighted average grant date fair value, granted (in dollars per share) 2.69  
Weighted average grant date fair value, forfeited (in dollars per share) 4.87  
Weighted average grant date fair value, outstanding at ending (in dollars per share) 4.80 $ 4.95
Weighted average grant date fair value, expected to vest and exercisable (in dollars per share) 4.80  
Weighted average grant date fair value, exercisable (in dollars per share) $ 5.00  
Weighted Average Remaining Contractual    
Weighted average remaining contractual, outstanding 6 years 9 months 18 days 7 years 10 months 24 days
Weighted average remaining contractual life, expected to vest and exercisable 6 years 9 months 18 days  
Weighted average remaining contractual life, exercisable 7 years